The following information is based on a press release from Biotie Therapies Corp. (Biotie) published on January 19, 2016 and may be subject to change.
Acorda Therapeutics, Inc. has announced a cash offer to acquire all outstanding shares of Biotie, whereby every one (1) Biotie share held entitles their holder to a cash payment of EUR 0.2946 per share. If Biotie, as a result of the offer, requests for a de-listing of the underlying share or if the trading in the same is considered to be insufficient to support related derivatives trading, NASDAQ OMX Derivatives Markets will (1) set a new expiration day for options and forwards contracts in Biotie (BTH1V3) and (2) settle the contracts at Fair Value.
For further information, please see the attached file.